Ipratropium nasal | |
What is it? | Antimuscarinic |
Mechanism of action | Antisecretory with bronchodilator properties |
Starting dose | 41 μg (two sprays) 6–8 hourly prn |
Time to onset of effect | 15–30 min17 |
Formulation | Nasal spray |
Indication | Rhinorrhoea Bronchial secretions Respiratory secretions |
Common adverse effects | Dizziness; dry mouth; headache; urinary disorders; vision disorders; vomiting; tachycardia; GI dysmotility; oropharyngeal irritation; bronchoconstriction16 |
Contraindications | Tachycardia >100 Cardiac conduction disorders16 |
Caution | Narrow angle glaucoma Bladder outflow obstruction Cystic fibrosis |
Licence | ‘off label’ use of licensed product |
Benefits | Easy to use |
Risks | It is unknown whether sufficient systemic absorption is achieved via the intranasal route to improve bronchial and respiratory secretions |
Cost | £6.54 for 180×21 μg/dose nasal spray |